Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Opinion Pieces Examine Recent Public Opinion Polls On Abortion
Two newspapers recently published opinion pieces on abortion-related public opinion polls. Summaries appear below.~ Steven Kull, Baltimore Sun: Although "many Americans feel morally conflicted about" abortion, it is a "common error to believe that the American electorate is deeply divided about how the government should deal with" the procedure, Kull -- director of WorldPublicOpinion.org and the Program on International Policy Attitudes at the University of Maryland -- writes in a Sun opinion piece. He adds that "there is substantial consensus that the government should not criminalize abortion." According to Kull, a new CNN poll found that 68% of respondents believe Roe v. Wade should not be overturned, and a recent WorldPublicOpinion.org poll found that when asked, "Do you think the government should be involved in trying to discourage abortion or do you think the government should leave these matters to the individual," 69% said that the matter should be left to the individual. Kull adds that "of the 29% who said that the government should be involved in trying to discourage abortions, a remarkably low 8% favored using criminal enforcement methods." According to Kull, other polls have found if "given a middle option -- somewhere between strict prohibition and government permission -- a significant number will choose it." Kull writes that "once the moral question is differentiated from the question of how the government should act, it does appear that there is substantial consensus that abortion should not be criminalized." He concludes, "Once the option of criminal enforcement is taken off the table, constructive options are more likely to emerge and can be an effective focus for the energies freed up from the incessant debates about abortion" (Kull, Baltimore Sun, 5/22).~ Cheryl Wetzstein, Washington Times: "It"s rather ironic that as the most pro-choice government in U.S. history settles into its seats," a Gallup poll "finds that most Americans are pro-life," columnist Wetzstein writes in a Times opinion piece. She adds, "Some observers have tried to pooh-pooh this result, but it doesn"t surprise me for two reasons." Wetzstein writes that her "experience with youth, both personally and professionally, is that they often recoil at abortion," adding, "So I find a pro-life trend in youth to be quite plausible." She continues, "Second, I think some aging baby boomers are changing their views," adding, "People generally become more conservative and self-reflective with age. Legacies matter. Hindsight is 20/20. Regrets appear." Wetzstein concludes, "My suspicion is that in more than a few cases, baby boomers who were willing to have abortions are not at ease with the idea of losing their grandchildren," adding, "It may be that in the autumn of life, being "pro-life" has a whole new meaning" (Wetzstein, Washington Times, 5/26).
generic viagra online
Pomegranate For Prostate Cancer
Pomegranate juice may be beneficial in men who have undergone standard treatment for localized prostate cancer, according to a long-term study presented at the 104th Annual Scientific Meeting of the American Urological Association.
News of the day
Today's Selection Of Opinions And Editorials
Obama"s Plan Isn"t The Answer The Washington Post
Public Health

With Vandetanib (Zactima™) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented At American Society Of Clinical Oncology

Data from the Phase III ZODIAC1 study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvement in progression-free survival (PFS), the length of time a patient lives without their cancer growing (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; PAbout vandetanib Vandetanib has a unique profile that fights cancer through two clinically proven mechanisms - by blocking the development of tumour blood supply (anti-angiogenesis or anti-VEGFR), and by blocking the growth and survival of the tumour itself (anti-EGFR). Vandetanib also inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer. About the Phase III studies in NSCLC ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) is a Phase III randomised, double-blind, placebo-controlled study evaluating the combination of vandetanib 100mg once daily plus docetaxel versus docetaxel alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer therapy. It enrolled 1391 patients at 250 centres throughout Europe, North America, South America and Asia Pacific. ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) is a randomised, double-blind, placebo-controlled Phase III study evaluating the combination of vandetanib 100mg with pemetrexed versus pemetrexed alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer therapy. It enrolled 534 patients at 160 centres across 23 countries. ZEST (ZACTIMA Efficacy Study versus Tarceva) is a Phase III randomised, double-blind, multi-centre study to assess the efficacy of vandetanib 300mg versus erlotinib in patients with locally advanced or metastatic NSCLC after failure of at least one prior anti-cancer therapy. It enrolled 1240 patients at 171 centres across 22 countries. ZEPHYR (ZACTIMA Efficacy trial for NSCLC Patients with HistorY of EGFR-TKI and chemo-Resistance) is a Phase III, randomised, double-blind, parallel-group, multi-centre study evaluating the efficacy of ZACTIMA 300mg plus best supportive care versus best supportive care in patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after prior therapy with an EGFR inhibitor. The study is running in approximately 170 centres across 23 countries. ZETA (Zactima Efficacy in Thyroid Cancer Assessment) is a phase III, randomized, double-blind, placebo-controlled, multi-centre study, evaluating once-daily ZACTIMA 300mg as a monotherapy in advanced medullary thyroid cancer. About lung cancer - Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this devastating disease - more than breast, colon and prostate cancer combined4. - Non-small cell lung cancer accounts for around 85% of all lung cancers5. - If lung cancer is detected at early stages, before it has spread to other organs or lymph nodes, around half of patients can survive for five years or more. However, few lung cancers are found at this early stage and it is normally diagnosed at the advanced stage, when five year survival falls to approximately 15%6. Reference List (1) Herbst, R. et al. Vandetanib plus docetaxel vs docetaxel as 2nd-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). ABS 31495. ASCO. 2009. (2) De Boer, R. et al. Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). ABS 31867, ASCO. 2009. (3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ABS 31610. ASCO. 2009. (4) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004. (5) Ginsberg RJ. et al. Cancer: Principles and Practices of Oncology. 5th ed; 858-911. 1997. 6th ed. 925-983. 2001. (6) Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging 1999; 14(4):228-234. Astra Zeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009